T-lymphocyte subsets in peripheral blood and liver tissue of patients with chronic hepatitis B and C

In Vivo

Volumn 25, Issue 5, 2011, Pages 833-840

  Dimitropoulou, Dimitra ^a   Karakantza, Marina ^a   Tsamandas, Athanassios C ^a   Mouzaki, Athanasia ^a   Theodorou, George ^a   Gogos, Charalambos A ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Hepatitis B; Hepatitis C; T Cell lymphocyte subsets

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN;

ARTICLE; BLOOD; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER; LIVER BIOPSY; MAJOR CLINICAL STUDY; T LYMPHOCYTE; VIRUS CARRIER;

EID: 79960652922     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. World Health Organization: Department of Communicable Disease Surveillance and Response. Hepatitis B. WHO Fact Sheets (http:www.who.int). Accessed: September 24, 2004.
2. NIH Consensus Statement on Management of Hepatitis C. NIH Consens State Sci Statements 19: 1-46, 2002.
3. Rehermann B and Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-219, 2005.
4. Neumann-Haefelin C, Blum HE, Chisari FV and Thimme R: T-Cell response in hepatitis C virus infection. J Clin Virol 32: 75-85, 2005. (Pubitemid 40093957)
5. Stoop JN, Molen RG, Kuipers EJ, Kusters JG and Janssen HL: Inhibition of viral replication reduces regulatory T-cells and enhances the antiviral immune response in chronic hepatitis B. Virology 361: 141-148, 2007. (Pubitemid 46551232)
6. Tulek N, Saglam SK, Saglam M, Turkyilmaz R and Yildiz M: Soluble IL-2 receptor and IL-10 levels in patients with chronic hepatitis B infection. Hepatogastroenterology 47: 828-831, 2000. (Pubitemid 30417303)
7. Khettry U, Anand N, Gordon FD, Jenkins RL, Tahan SR, Loda M et ai: Recurrent hepatitis B and C and combined hepatitis B and C in liver allografts: a comparative pathological study. Hum Pathol 31: 101-108, 2000. (Pubitemid 30054394)
8. + T-cells with viral clearance in acute hepatitis C. J Infect Dis 181: 1528-1536, 2000. (Pubitemid 30387741)
9. Lechner F, Wong DK, Dunbar P, Chapman R, Chung R, Dohrenwend P et al: Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191: 1499-1512, 2000.
10. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien D et al: Analysis of a successful immune response against hepatitis C virus. Immunity 10: 439-449, 1999. (Pubitemid 29205480)
11. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C et al: Viral and immunological determinate of hepatitis C virus clearance, persistance and disease. Proc Natl Acad Sci USA 99: 15661-15668, 2002. (Pubitemid 35403988)
12. Cox AL, Mosbuger T, Lauer GM, Pardoll D, Thomas DL and Ray SC: Comprehensive analyses of CD8 T-cell responses durind longitudinal study of acute human hepatitis C. Gastroenterology 132: 654-666, 2007.
13. Koziel MJ, Dudley D and Wong J: Intrahepatic cytotoxic T-lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 149: 3339-3344, 1992.
14. Ishak K, Baptista A, Bianchi L et al: Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699, 1995.
15. Tsamandas AC, Syrokosta I, Thomopoulos K, Zolota V, Dimitropoulou D, Liava A et al: Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: a clinicopathologic study. Liver Int 26(7): 817-826, 2006. (Pubitemid 44165249)
16. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C et al: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2009 (Epub ahead of print) PMID:19447770.
17. Scopa CD, Vagianos C, Kardamakis D, Kourelis TG, Kalofonos HP and Tsamandas AC: BCL2/BAX ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 9(4): 329-334, 2001. (Pubitemid 33098142)
18. Sprengers D, van de Molen RG, Kusters JG, Hansen B, Niesters HG and Schalm SW: Different composition of intrahepatic lymphocytes in the immune-tolerance and immune-clearance phase of chronic hepatitis B. J Med Virol 78: 561-568, 2006.
19. Sing G, Butterworth L, Chen X, Bryant A and Cooksley G: Composition of peripheral blood lymphocyte populations during different stages of chronic infection with hepatitis B virus. J Viral Hepat 5: 83-93, 1998. (Pubitemid 28383572)
20. Mi YG, Liang SR, Zhang H, Zheng SW, Li ST and Cao WK: The correlation of HbeAg expression and HBV-DNA in serum or peripheral blood monuclear cells in patients with chronic hepatitis B. Zhongua Shiyan He Linchuang Bingduxue Zazhi 21: 261-263, 2007.
21. Bertolletti A and Gehring AJ: The immune response during hepatitis B virus infection. J Gen Virol 87: 1439-1449, 2006.
22. Reherman B, Lau D, Hoofnagle JH and Chisari FV: Cytotoxic T-lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97: 1655-1665, 1996. (Pubitemid 26105477)
23. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimman KA, Purcell RH et al: CD8(+) T-cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77: 68-76, 2003. (Pubitemid 36004947)
24. Fuller MJ and Zajac AJ: Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol 170: 477-486, 2003. (Pubitemid 36026174)
25. Tian Y and Li TS: The relationship between clinical outcome of hepatitis B virus infection and the host's cellular immunity. Zhonghua Nei Ke Za Zhi 46(72): 1014-1017, 2007.
26. You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Chen H et al: Hepatitis B virus DNA is more powerful than HBeAg in predicting peripheral T-lymphocyte subpopulatons in chronic HBV-infected individuals with normal liver function tests. World J Gastroenterol 14(25): 3710-3718, 2008.
27. You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li Y et al: Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis 8: 123, 2008.
28. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Gavallo C et al: Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33: 963-971, 2001. (Pubitemid 32246646)
29. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S et al: Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B. J Clin Invest 102: 968-975, 1998. (Pubitemid 28419565)
30. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Misalle G et al: Transient restoration of anti-viral T-cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39: 595-605, 2003.
31. You J, Zhang Y, Chen H, Sriplung H, Geater A et al: Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load. World J Gastroenterol 15: 3382-3393, 2009.
32. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical computing, Vienna, Austria. ISBN 3-900051-07-0. Available from: URL:http//www.R-project.org
33. Milich DR, Jones JE, Hughes JL, Price J, Raney AK and McLachlan A: Is a function of the secreted hepatitis Be antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 87: 6599-6603, 1990.
34. Milich DR, Chen MK, Hughes JL and Jones JE: The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for presistance. J Immunol 160: 2013-2021, 1998. (Pubitemid 28106492)
35. Milich DR and Liang TG: Exploring the biological basis of hepatitis Be antigen in hepatitis B virus infection. Hepatology 38: 1075-1076, 2003.
36. Wong DK, Dudley DD, Dohrenwend PB, Lauer GM, Chung RT, Thomas DL et al: Detection of diverse hepatitis C virus-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV J Virol 75: 1229-1235, 2001.
37. Ishii S and Koziel M: Immune responses during acute and chronic infection with hepatitis C virus. Clinical Immunol 128: 133-147, 2008.
38. Grabowska A, Lechner F, klenerman P, Tighe P, Ryder S, Ball J et al: Direct ex vivo comparison of the breadth and specificity of the T-cells in the liver and the peripheral blood of patients with chronic HCV infection. J Immunol 31: 2388-2394, 2001. (Pubitemid 32785357)
39. + T-cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 96: 5692-5697, 1999.
40. Kaneko T, Moriyama T, Udaka K, Hiroishi K, Kita H, Okamoto H, Yagita H et al: Impaired induction of cytotoxic T-lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope. Eur J Immunol 27: 1782-1787, 1997. (Pubitemid 27302864)
41. + T-cell failure in chronic hepatitis C virus infection. Hepatology 47: 1824-1836, 2008.
42. Timm J, Li B, Daniels MG, Bhattacharya T, Reyor L, Allgaier R et al: Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 46: 339-349, 2007. (Pubitemid 47344768)
43. + T-cells in chronic hepatitis C. J Immunol 169: 3447-3458, 2002. (Pubitemid 35013196)
44. + T-cell failure during chronic hepatitis C virus infection. Hepatology 42: 828-837, 2005.
45. + T-cells in the liver of patients with chronic HCV infection. J Hepatol 44: 475-483, 2006.
46. Erickson AL, Kimura, Igarashi S, Eichelberg J, Houghton M, Sidney J et al; The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T-lymphocytes. Immunity 15: 885-895, 2001.
47. + T-lymphocyte correlate to intensity of interface hepatitis in chronic hepatitis C. Rev Inst Med 49(6): 371-378, 2007.
48. Pernollet M, Jouvin-Marce E, Leroy V, Vigan I, Zarski JP and Marche PN: Simultaneus evaluation of lymphocyte subpopulations in the liver and in the peripheral blood monuclear cells of HCV infected patients:relationship with histological lesions. Clin Exp Immunol 130: 518-525, 2002. (Pubitemid 35418337)